Biologics: The role of delivery systems in improved therapy

Biologics: Targets and Therapy

Volumn 8, Issue , 2014, Pages 107-114

  Škalko Basnet, Nataša ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Biologics; Drug delivery systems; Medical devices

Indexed keywords

BILOSOME; BIOLOGICAL PRODUCT; DRUG CARRIER; LIPOSOME; MICROSPHERE; NANOPARTICLE; POLYGLACTIN; POLYLACTIC ACID; SOLID LIPID MICROPARTICLE; UNCLASSIFIED DRUG;

BIODEGRADABILITY; CHEMICAL PROCEDURES; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; IMPLANT; LIPOSOMAL DELIVERY; LIQUID GELLING; MICROCAPSULE; MICROCRYSTALLINE SUSPENSION; NANOPHARMACEUTICS; NON INVASIVE PROCEDURE; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; REVIEW; SELF ASSEMBLY SYSTEM; SOLID IMPLANT; SUSTAINED RELEASE FORMULATION; WATER BASED PARTICULATE SYSTEM;

EID: 84897854012     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S38387     Document Type: Review

References (51)

1. Kling J. Fresh from the biotech pipeline - 2011. Nat Biotechnol. 2012;30(2):128-131.
2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10): 767-774.
3. Ezan E. Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev. 2013;65(8):1065-1073.
4. Poelstra K, Beljaars L, Melgert BN. Cell-specifc delivery of biologicals: problems, pitfalls and possibilities of antifbrotic compounds in the liver. Drug Discov Today. 2013;18(23-24):1237-1242.
5. Chung S W, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20(6):481-501.
6. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classifcation. Nat Rev Drug Discov. 2008;7(1):21-39.
7. Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism and excretion studies of therapeutic biologicals. AAPS J. 2012;14(4):781-791.
8. Martin-Moe S, Lim FJ, Wong RL, Sreedhara A, Sundaram J, Sane SU. A new roadmap for biopharmaceutical drug product development: integrating development, validation and quality by design. J Pharm Sci. 2011;100(8):3031-3043.
9. Richard J. Parenteral biologics delivery: recent progresses, key challenges and perspectives. European Journal of Parenteral and Pharmaceutical Sciences. 2012;17(3):94-109.
10. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101-2141.
11. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60-71.
12. Kronenberg S, Baumann A, de Haan L, et al. Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov Today. 2013;18(23-24):1138-1143.
13. Burgess BE. Optimizing drug delivery for modern biologics. BioPharm International. 2012;25(5):30-32.
14. Cázares-Delgadillo J, Ganem-Rondero A, Kalia YN. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm. 2011;78(2): 278-288.
15. Reithmeier H, Hermann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001;73(2-3):339-350.
16. Govardhan C, Khalaf N, Jung C W, et al. Novel long-acting formulation of human growth hormone. Pharm Res. 2005;22(9):1461-1470.
17. Whitehead K, Shen Z, Mitragotri S. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release. 2004;98(1):37-45.
18. El Khafagy S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Del Rev. 2012;64(6):531-539.
19. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223-3230.
20. Sonaje K, Lin YH, Juang JH, Wey S P, Chen CT, Sung H W. In vivo evaluation of safety and effcacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 2009;30(12):2329-2339.
21. Krol S, Ellis-Behke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. Nanomedicine. 2012;8(Suppl 1):S69-S76.
22. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2): 75-85.
23. Thompson CJ, Tetley L, Uchegbu IF, Cheng W P. The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery. Int J Pharm. 2009;376(1-2):46-55.
24. Shukla A, Katare O P, Singh B, Vyas S P. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 2010;385(1-2):47-52.
25. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine. 2011;6:1155-1166.
26. Zhang N, Ping QN, Huang GH, Xu WF. Investigation of lectin-modifed insulin liposomes as carriers for oral administration. Int J Pharm. 2005;294(1-2):247-259.
27. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release. 2008;125(3):236-245.
28. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-1568.
29. Builders PF, Kunle OO, Okpaku LC, Builders MI, Attama AA, Adikwu MU. Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin. Eur J Pharm Biopharm. 2008;70(6):777-783.
30. Dünnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnürch A. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm. 2011;408(1-2): 191-199.
31. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J Control Release. 2006;114(1):1-14.
32. Card J W, Magnuson BA. A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G956-G967.
33. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release. 2003;87(1-3):187-198.
34. Washington N, Washington C, Wilson CG, editors. Physiological Pharmaceutics, Barriers to Drug Absorption. 2nd ed. London: Taylor and Francis; 2001:199-220.
35. Steyn D, Du Plessis L, Kotzé A. Nasal delivery of recombinant human growth hormone: in vivo evaluation with Pheroid technology and N- trimethyl chitosan chloride. J Pharm Pharm Sci. 2010;13(2): 263-273.
36. Du Plessis LH, Lubbe J, Strauss T, Kotzé AF. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride. Int J Pharm. 2010;385(1-2):181-186.
37. Dhuria S V, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanism and experimental considerations. J Pharm Sci. 2010;93(4):1654-1673.
38. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Del Rev. 2012;64(7):614-628.
39. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198-209.
40. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2005;2(3):533-548.
41. Jeon SO, Hwang HJ, Oh DH, et al. Enhanced percutaneous delivery of recombinant human epidermal growth factor employing nano-liposome system. J Microencapsul. 2012;29(3):234-241.
42. Qiu Y, Qin G, Zhang S, Wu Y, Xu B, Gao Y. Novel lyophilized hydrogel patches for convenient and effective administration of microneedle-mediated insulin delivery. Int J Pharm. 2012;437(1-2):51-56.
43. Vanić Z, Škalko-Basnet N. Nanopharmaceuticals for improved topical vaginal therapy: can they deliver? Eur J Pharm Sci. 2013;50(1): 29-41.
44. Chung HJ, Lee Y, Park TG. Thermo-sensitive and biodegradable hydrogels based on stereocomplexed Pluronic multi-block copoly-mers for controlled protein delivery. J Control Release. 2008;127(1): 22-30.
45. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm. 2008;355(1-2):1-18.
46. Jordan F, Naylor A, Kelly CA, Howdle SM, Lewis A, Illum L. Sustained release hGH microsphere formulation produced by a novel supercritical fuid technology: in vivo studies. J Control Release. 2010;141(1): 153-160.
47. van Dijkhuizen-Radersma R, Hesseling SC, Kaim PE, De Groot K, Bezemer JM. Biocompatibility and degradation of poly(ether-ester) microspheres: in vitro and in vivo evaluation. Biomaterials. 2002;23(24):4719-4729.
48. Maschke A, Becker C, Eyrich D, Kiermaier J, Blunk T, Göpferich A. Development of a spray congealing process for the preparation of insulin-loaded lipid microparticles and characterization thereof. Eur J Pharm Biopharm. 2007;65(2):175-187.
49. Chan Y P, Meyruiex R, Kravtzoff R, Nicolas F, Lundstrom K. Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv. 2007;4(4):441-451.
50. Peter F, Bidlingmaier M, Savoy C, Ji HJ, Saenger PH. Three-year effcacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH defciency (GHD). J Clin Endocrinol Metab. 2012;97(2):400-407.
51. Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 2006;6:5.